AMLX today
$30.08+$0.22 (+0.74%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourBearish
1 hourStrong Bullish
15 minBullish
5 minStrong Bullish
Daily trend turns up above $12.37
Key levels
Support$15.15
Support$12.37
Latest news & SEC filings
AnalystMizuho keeps Outperform rating on Amylyx Pharmaceuticals, lifts price target to $39
AnalystMizuho lifts Amylyx Pharmaceuticals target to $39, keeps Outperform rating
EarningsAmylyx Pharmaceuticals posts Q3 2026 financial results
EarningsAmylyx Pharma reports Q3 EPS of $(0.38), matching estimates
All AMLX news →About Amylyx
Amylyx Pharmaceuticals develops experimental medicines for hormonal disorders and nerve-related diseases. Its programs include avexitide for low blood sugar after weight-loss surgery and in infants with excess insulin, AMX0035 for Wolfram syndrome, AMX0114 for ALS, and AMX0318 for similar rare conditions. The company is based in the United States and uses outside manufacturers to make its trial supplies.
Based on the company's 10-K filed Mar 3, 2026.
Nasdaq · Healthcare
Amylyx Pharmaceuticals, Inc. (AMLX)
What Is the Price Target for AMLX?
SEPT Low Target
$39.00
SEPT Mid Target
$52.00
SEPT High Target
$57.00
Analyst Consensus
$52.00
Is AMLX a Buy or Sell Right Now?
Thesis
- •Revenue growing -77.1% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for AMLX.
Start Free Trial →Is AMLX Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
P/B, Analyst Consensus
Fair Value
$40.41
25
Moat Score
NONE
4/9
Piotroski Score
56.9
Altman Z-Score
What Is Smart Money Doing with AMLX?
Insider Signal
SELLING
1 buys / 11 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| FRATES JAMES M | officer | Buy | 20,000 | $138K | Nov 10, 2026 |
| FRATES JAMES M | officer | Sale | 12,800 | $388K | Nov 10, 2026 |
| FRATES JAMES M | officer | Sale | 7,200 | $223K | Nov 10, 2026 |
| FRATES JAMES M | officer | Buy | 20,000 | $138K | Nov 9, 2026 |
| FRATES JAMES M | officer | Sale | 7,700 | $226K | Nov 9, 2026 |
| FRATES JAMES M | officer | Sale | 12,300 | $370K | Nov 9, 2026 |
| Klee Justin B. | director officer | Sale | 37,483 | $1.1M | Nov 9, 2026 |
| Klee Justin B. | director officer | Sale | 62,517 | $1.9M | Nov 9, 2026 |
| Cohen Joshua B | director officer | Sale | 38,105 | $1.1M | Nov 9, 2026 |
| Cohen Joshua B | director officer | Sale | 61,895 | $1.9M | Nov 9, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →AMLX Growth Story
Revenue YoY
-77.1%
3yr Revenue CAGR
574.3%
EPS Growth YoY
65.46%
FCF Growth YoY
26.4%
Revenue Trend
STRONG
Dark Pool Trades for AMLX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for AMLX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 19:13:43 | $30.16 | 1,100 | $$33K | BUY |
| 19:13:43 | $30.14 | 1,100 | $$33K | BUY |
| 18:14:49 | $29.81 | 2,504 | $$75K | BUY |
| 18:04:05 | $29.76 | 2,000 | $$60K | BUY |
| 18:00:55 | $29.84 | 1,100 | $$33K | BUY |
5 dark pool trades shown · $$233K preview volume
Real-time institutional flow, block trades, and net positioning
What Traders Are Saying About AMLX
2 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for AMLX. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
$AMLX director officer Klee Justin B. sold 62,517 shares at $30.11, $1.88M, Form 4 filed Thu Nov 12.
Zone Setup — $AMLX (Amylyx Pharmaceuticals, Inc.) Price: $22.32 | Zone: $18.08 — $24.60 Conviction: HIGH | Analyst upside: +16.4% Near resistance (65% of range) — breakout watch. Strong positive new...
Join 3,500+ traders discussing AMLX in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Amylyx Pharmaceuticals, Inc. (AMLX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →AMLX — frequently asked questions
What is AMLX stock price today?
Amylyx Pharmaceuticals, Inc. (AMLX) is at $30.08, up 0.74% (+$0.22) at the Nov 13, 2026 close.
Why is AMLX stock moving today?
Latest AMLX news — Nov 10, 2026: Mizuho keeps Outperform rating on Amylyx Pharmaceuticals, lifts price target to $39 · Nov 9, 2026: Mizuho lifts Amylyx Pharmaceuticals target to $39, keeps Outperform rating
What is the AMLX price target?
The average analyst price target for AMLX is $52.00, ranging from $39 to $57, based on 5 analysts. Latest: Citigroup maintains on Oct 15, 2026.
What do analysts rate AMLX?
Analyst ratings for AMLX: 0 Buy, 11 Hold, 0 Sell — consensus Hold.
Did AMLX beat earnings?
AMLX last reported on Aug 6, 2026: EPS -$0.39 vs -$0.36 expected — a miss of 8.1%.
Does AMLX pay a dividend?
AMLX does not currently pay a dividend.
What are AMLX support and resistance levels?
Support: $15.15, $12.37, $10.74.
What are insiders doing with AMLX?
Insider activity: SELLING, 1 buys and 11 sells in the last 90 days.
What is the latest news on AMLX?
Nov 10, 2026: Mizuho keeps Outperform rating on Amylyx Pharmaceuticals, lifts price target to $39 · Nov 9, 2026: Mizuho lifts Amylyx Pharmaceuticals target to $39, keeps Outperform rating · Nov 5, 2026: Amylyx Pharmaceuticals posts Q3 2026 financial results